Pathogenesis and treatment of IgA Nephropathy

Vinci Congress Center , Tours , France

Date
September 16, 2016

Location
Vinci Congress Center - 26, Boulevard Heurteloup , Tours , France

Organising Society/Institution/University
ERA-EDTA Immunonephrology Working Group

Local Coordinator/Contact Person for information
Dr. Renato Monteiro, E-mail: renato.monteiro@inserm.fr

Organising Secretariat

Center for Research on Inflammation (CRI) - INSERM (Institut national de la

santé et de la recherche médicale) Unit 1149, Phone: +33 1.57.27.77.55

Short Description

IgA nephropathy is the most common glomerular disease, and a common cause of

chronic renal failure. In many national registries it accounts for around 10% of all

dialysis and transplant patients. 20-30% of patients with IgA nephropathy develop

end stage renal disease (requiring dialysis or a kidney transplant) within 10-20 years

from the diagnosis.

Hypertension, proteinuria and reduced renal function at diagnosis are identified as

the clinical risk factors for a poor outcome. On renal biopsy, an interstitial infiltrate is

the most commonly reported marker of adverse outcome. Multiple genetic loci

associated with disease risk have been identified. The prevalence of risk alleles

varies geographically, highest in eastern Asia and northern Europe, fewer in other

parts of Europe and North America, and the least in Africa.

There is growing evidence that IgAN is an immune complex -mediated disease. To

date, three key molecules have been implicated in IC formation, correlating with

disease progression: galactose-deficient IgA1 (Gd-IgA1), IgG anti-Gd-IgA1 antibodies,

and soluble CD89 (a Fc receptor for IgA). A better understanding of the multi-step

process of pathogenesis of IgA nephropathy and the genetic and environmental

contributing factors will lead to development of biomarkers to identify patients with

progressive disease who would benefit from a future disease-specific therapy.

This course will be held in the contest of the "14th International Symposium on IgA

Nephropathy". The scientific programme of the symposium touches most of the

state-of-the-art work in the field and the interactions between the attendees will give

the opportunity to review and discuss the topics.

The aim of the course is to provide the participants with the recent progress in the

genetics, pathogenesis and therapy of IgA nephropathy. The topics covered are

outstanding and they could offer the possibility of new investigations in the field.

Scientific content of the educational event:

A high level scientific update will be given in the following area of IgA nephropathy

Lectures (30 minutes + 30 minute discussion):

1) Genetics and environmental factors in IgAN: A. Gharavi (USA)

2) From genetics to tonsillar flora in IgAN: I. Narita (Japan)

3) Intestinal dysbiosis in IgAN: L. Gesualdo (Italy)

4) Role of streptococcal proteins in IgAN: D. Karpman (Sweden)

5) Pathogenic role of gluten in IgAN: R. Monteiro (France)

6) Meet the experts session- Genetics and environment in IgAN

7) Corticosteroids : data from VALIGA study: V. Tesar, (Czech Republic)

8) ARA surrogate end-points for IgAN: D. Cattran (Canada)

9) STOP IgAN Trial: J. Floege (Germany)

10) The NEFIGAN Trial: B. Fellstrom (Sweden)

11) Meet the experts session- Conventional and innovative therapy for IgAN.

Travel Grant

Click here to download the Travel Grant application

Details/General Information
Website: www.iigann-tours-2016.com

Course Programme
Click here to download the programme.